<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Partial list of medicines and other substances thought to be unsafe or safe in individuals with G6PD deficiency</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Partial list of medicines and other substances thought to be unsafe or safe in individuals with G6PD deficiency</h1>
<div class="graphic"><div class="figure"><div class="ttl">Partial list of medicines and other substances thought to be unsafe or safe in individuals with G6PD deficiency</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Medicines and other substances likely to be <span style="color: #ff0000;">UNSAFE</span> in moderate to severe G6PD <span style="white-space: nowrap;">deficiency*</span></td> </tr> <tr> <td class="subtitle2_single">Medications</td> </tr> <tr> <td class="indent1">Chlorpropamide</td> </tr> <tr> <td class="indent1">Dabrafenib</td> </tr> <tr> <td class="indent1">Dapsone (diaminodiphenyl sulfone)</td> </tr> <tr> <td class="indent1">Fluoroquinolones (ciprofloxacin, moxifloxacin, norfloxacin, ofloxacin)<sup>¶</sup></td> </tr> <tr> <td class="indent1">Methylene blue (methylthioninium chloride)<sup>Δ</sup></td> </tr> <tr> <td class="indent1">Nalidixic acid<sup>◊</sup></td> </tr> <tr> <td class="indent1">Nitrofurantoin, nifuratel, and nitrofurazone (nitrofural)<sup>◊</sup></td> </tr> <tr> <td class="indent1">Phenazopyridine (pyridium)</td> </tr> <tr> <td class="indent1">Primaquine and tafenoquine</td> </tr> <tr> <td class="indent1">Rasburicase and pegloticase </td> </tr> <tr class="divider_bottom"> <td class="indent1">Sulfonylureas (eg, glipizide, glyburide [glibenclamide])</td> </tr> <tr> <td class="subtitle2_single">Chemical exposures and foods</td> </tr> <tr> <td class="indent1">Fava beans</td> </tr> <tr> <td class="indent1">Henna compounds (black and red Egyptian)</td> </tr> <tr> <td class="indent1">Naphthalene (mothballs, lavatory deodorant)</td> </tr> <tr> <td class="indent1">Phenylhydrazine</td> </tr> <tr class="divider_bottom"> <td class="indent1">"RUSH" (isobutyl nitrite, amyl nitrite)</td> </tr> <tr class="divider_top"> <td class="subtitle1_single">Medicines that are <span style="color: #ff0000;">PROBABLY SAFE</span> given in usual therapeutic doses in G6PD deficiency*; NOTE: some of these were previously considered unsafe; safety in Class I variants is generally not <span style="white-space: nowrap;">known</span></td> </tr> <tr> <td class="indent1">Acetaminophen (Tylenol, Paracetamol)</td> </tr> <tr> <td class="indent1">Aminophenazone, dipyrone, and metamizole (NSAIDs)<sup>◊</sup></td> </tr> <tr> <td class="indent1">Antazoline (antihistamine)</td> </tr> <tr> <td class="indent1">Antipyrine (phenazone)</td> </tr> <tr> <td class="indent1">Ascorbic acid (vitamin C)</td> </tr> <tr> <td class="indent1">Aspirin (acetylsalicylic acid)</td> </tr> <tr> <td class="indent1">Benzhexol (Artane)</td> </tr> <tr> <td class="indent1">Chloramphenicol</td> </tr> <tr> <td class="indent1">Chloroquine and hydroxychloroquine</td> </tr> <tr> <td class="indent1">Colchicine</td> </tr> <tr> <td class="indent1">Clotrimazole</td> </tr> <tr> <td class="indent1">Diphenhydramine (Benadryl)</td> </tr> <tr> <td class="indent1">Isoniazid</td> </tr> <tr> <td class="indent1">Levodopa (L-Dopa) and levodopa-carbidopa</td> </tr> <tr> <td class="indent1">Para-aminosalicylic acid</td> </tr> <tr> <td class="indent1">Para-aminobenzoic acid (PABA)</td> </tr> <tr> <td class="indent1">Phenylbutazone</td> </tr> <tr> <td class="indent1">Phenytoin</td> </tr> <tr> <td class="indent1">Probenecid (Benemid)</td> </tr> <tr> <td class="indent1">Procainamide (Pronestyl)</td> </tr> <tr> <td class="indent1">Pyrimethamine (Daraprim)</td> </tr> <tr> <td class="indent1">Quinine</td> </tr> <tr> <td class="indent1">Streptomycin</td> </tr> <tr> <td class="indent1">Sulfa-containing drugs<sup>§</sup> (sulfacetamide, sulfadiazine, sulfamethoxazole [Gantanol], trimethoprim-sulfamethoxazole, sulfamethoxypyridazine [Kynex], sulfanilamide, sulfisoxazole [Gantrisin])</td> </tr> <tr> <td class="indent1">Tiaprofenic acid</td> </tr> <tr> <td class="indent1">Trimethoprim</td> </tr> <tr> <td class="indent1">Tripelennamine (Pyribenzamine)</td> </tr> <tr> <td class="indent1">Vitamin K</td> </tr> </tbody></table></div><div class="graphic_lgnd">This is a general list and may not apply to all G6PD-deficient individuals. Use clinical judgment, and refer to UpToDate discussions, patient history, and other resources for additional information.</div><div class="graphic_footnotes">G6PD: glucose-6-phosphate deficiency; NSAIDs: nonsteroidal antiinflammatory drugs.<br/><br/>* Applies to Class I, II, and III G6PD variants. However, note that there is marked variability in reports. This list is based on evidence supporting a clear association with drug-induced hemolysis. Individual characteristics (ie, degree of G6PD deficiency, dose, presence of infection) will determine actual safety or injury. Medicines known to be unsafe in G6PD deficiency that are no longer in clinical use are excluded from this list. In cases where the patient truly requires the medication and G6PD status is unknown, it may be appropriate to administer and monitor closely.<br/>¶ Levofloxacin is not listed because some cases of hemolytic anemia with levofloxacin have been associated with a positive Coombs test.<br/>Δ Methylene blue is a component of some combination urinary tract products.<br/>◊ Not available in the United States.<br/>§ Sulfamethoxazole is widely used. Some cases of hemolysis in individuals with G6PD deficiency have been reported. Use with caution.</div><div class="graphic_reference">References:<br/><ol>
<li>​Beutler E. Glucose-6-phosphate dehydrogenase deficiency: A historical perspective. Blood 2008; 111:16.</li>
<li>Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008; 371:64.</li>
<li>G6PD deficiency favism association website: <a href="http://www.g6pd.org/en/G6PDDeficiency/SafeUnsafe/DaEvitare_ISS-it">http://www.g6pd.org/en/G6PDDeficiency/SafeUnsafe/DaEvitare_ISS-it</a>.</li>
<li>Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blood 2020.</li>
<li>Luzzatto L, Seneca E. G6PD deficiency: A classic example of pharmacogenetics with on-going clinical implications. Br J Haematol 2014; 164:469.</li>
<li>Youngster I, Arcavi L, Schechmaster R. Medications and glucose6-phosphate dehydrogenase deficiency. Drug Saf 2010; 33:713.</li></ol></div><div id="graphicVersion">Graphic 74254 Version 25.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
